<div id="readability-page-1"><div><ul> <li>Earlier this month, Soleno Therapeutics announced the passing of long-serving director and Audit Committee Chair William G. Harris, while indicating that existing Audit Committee member Andrew Sinclair, who qualifies as an “audit committee financial expert,” is expected to assume the chair role.</li> <li>At the same time, the company has attracted uniformly positive analyst attention following FDA approval of Vykat XR, currently the only approved therapy for hyperphagia in Prader-Willi syndrome, signaling a shift into a new phase of its corporate story.</li> <li>We will now examine how the Vykat XR approval, alongside Soleno’s evolving board leadership, shapes the company’s investment narrative going forward.</li> </ul><p>The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.</p><h2>What Is Soleno Therapeutics' Investment Narrative?</h2><p>To own Soleno today, you essentially have to believe that Vykat XR can scale from a first-in-class approval into a durable, commercially meaningful PWS franchise, while the company manages the costs and execution risk that come with that transition. The recent passing of longtime audit chair William Harris is a loss of deep biopharma finance experience, but the expected promotion of Andrew Sinclair, alongside the recent addition of finance veteran Mark Hahn, suggests governance continuity rather than disruption. Given that, the near term catalysts still sit squarely around Vykat XR launch metrics, payer uptake and progress toward narrowing substantial operating losses, rather than board changes. Key risks remain the rich valuation, continued unprofitability and relatively new leadership team, which could amplify any commercial missteps.</p><p> However, one governance and financial oversight risk may surprise new shareholders.  Soleno Therapeutics' shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.</p><h2>Exploring Other Perspectives</h2><figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4a7fce25-9ecf-4185-8ec6-6c01b5e9d8f4/chart/quote-price?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4a7fce25-9ecf-4185-8ec6-6c01b5e9d8f4/chart/quote-price"/><figcaption>SLNO 1-Year Stock Price Chart</figcaption></figure> <p>Four fair value estimates from the Simply Wall St Community span roughly US$43 to over US$430 per share, underscoring how differently individual investors see Soleno’s long term potential. Set against this wide dispersion, the company’s dependence on successful Vykat XR commercialization and a still unseasoned management team gives these contrasting views real weight, inviting you to examine several angles before forming a conclusion.</p><p>Explore 4 other fair value estimates on Soleno Therapeutics - why the stock might be worth over 8x more than the current price!</p><h2>Build Your Own Soleno Therapeutics Narrative</h2><p>Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.</p><ul><li>A great starting point for your Soleno Therapeutics research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.</li><li>Our free Soleno Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Soleno Therapeutics' overall financial health at a glance.</li></ul><h2>Contemplating Other Strategies?</h2><p>Every day counts. These free picks are already gaining attention. See them before the crowd does:</p><ul><li>Find companies with promising cash flow potential yet trading below their fair value.</li><li>Outshine the giants: these 26 early-stage AI stocks could fund your retirement.</li><li>Trump has pledged to &#34;unleash&#34; American oil and gas and these 22 US stocks have developments that are poised to benefit.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data     and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your     financial situation. We aim to bring you long-term focused analysis driven by fundamental data.     Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.     Simply Wall St has no position in any stocks mentioned.</em></p><div><p>Mobile Infrastructure for Defense and Disaster</p><p>The next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.</p><p>Get the investor briefing before the next round of contracts</p><p><span>Sponsored On Behalf of CiTech</span></p></div></div></div>

SLNO

<p>Soleno Therapeutics is experiencing a shift in its investment narrative following the FDA approval of Vykat XR, the only approved therapy for hyperphagia in Prader-Willi syndrome. The company is also undergoing board changes with Andrew Sinclair expected to assume the Audit Committee Chair role after the passing of William G. Harris. Analysts are optimistic about Vykat XR's potential, but risks include high valuation, unprofitability, and a new leadership team. Investors are encouraged to consider various perspectives on Soleno's long-term potential.</p>

Will Vykat XR Approval and Board Shift Reshape Soleno Therapeutics' (SLNO) Investment Narrative?